GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humanigen Inc (STU:0KB1) » Definitions » Short Interest

Humanigen (STU:0KB1) Short Interest


View and export this data going back to 2014. Start your Free Trial

What is Humanigen Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Humanigen's Short Interest

For the Biotechnology subindustry, Humanigen's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Humanigen's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humanigen's Short Interest distribution charts can be found below:

* The bar in red indicates where Humanigen's Short Interest falls into.


Humanigen (STU:0KB1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humanigen Inc (STU:0KB1) » Definitions » Short Interest
Comparable Companies
MYMX RSPI RBSH KRBP CNBX EVFM PPCB CALA QBIO RGMP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
830 Morris Turnpike, 4th Floor, Short Hills, NJ, USA, 07078
Website
https://www.humanigen.com
Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. It has one segment, which is related to the development of pharmaceutical products.

Humanigen (STU:0KB1) Headlines

No Headlines